ARS Pharmaceuticals Announces Planned Launch of neffyinSchools Program to Provide Life-Saving Needle Free Epinephrine to Eligible K-12 Schools at No Cost

Qualifying public and private K-12 Schools in the U.S. will be eligible to receive two free cartons (four single use doses) of neffy® (epinephrine nasal spray) 2mg for use in emergency treatment of allergic reactions including anaphylaxis Interested schools are encouraged to review applicable state laws and regulations to ensure neffy for undesignated use meets all requirements SAN DIEGO, Dec. 04, 2024 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to emp ...